27 November, 2024
Green innovation: Gesynta's commitment to sustainability
22 November, 2024
Empowering Women's Health: Meet the Artemis Foundation
12 October, 2024
Understanding inflammatory arthritis: Early intervention is crucial
2 October, 2024
Building a more inclusive workplace: Addressing menstrual health
10 September, 2024
From Luxembourg to Australia: Global advocacy for endometriosis
2 September, 2024
Unraveling the complexity: Endometriosis and comorbidities
19 August, 2024
Beyond the mimics: Why endometriosis needs a team approach
5 August, 2024
Missed & misunderstood: Unmasking endometriosis in young women
15 July, 2024
11 lost years. Can we shorten the diagnosis journey?
1 July, 2024
Endometriosis: A call for comprehensive care and early intervention
1 June, 2024
Could Endometriosis Be Affecting Your Fertility?
15 May, 2024
Join us in Bucharest! Sharing vipoglanstat's potential for better endometriosis treatment
1 May, 2024
May is Arthritis Awareness Month: Understanding Inflammatory Arthritis
19 April, 2024
Gesynta Pharma presents e-poster on vipoglanstat at SEUD 2024 in Geneva
27 March, 2024
Silent struggle, unseen impact: Endometriosis demands equality in research and awareness
19 March, 2024
US government proposing $12 billion fund for women's health research
8 March, 2024
International Womens Day: Break the bias in pain research
1 March, 2024
Endometriosis: Chronic Pain, Daily Struggles
24 February, 2024
Study on systemic sclerosis published in Rheumatology
5 February, 2024
We are hiring! VP Clinical Development – endometriosis and other inflammatory diseases
19 January, 2024
WEF in Davos: Women's health needs are overlooked
3 January, 2024
Action is needed to improve endometriosis diagnosis and care
6 December, 2023
New initiatives in women’s health and endometriosis in Sweden, the EU, Denmark, and the United States
27 October, 2023
Patient apps – a step forward in the diagnosis and treatment of endometriosis?
24 August, 2023
GS-073 approved for clinical development in chronic inflammatory pain
10 August, 2023
Towards a deeper understanding of endometriosis
22 May, 2023
INN assigned: vipoglanstat (GS-248) for the treatment of endometriosis
1 March, 2023
Endometriosis truly needs an Awareness Month
20 October, 2022
Gesynta Pharma prepares Phase II study of GS-248 in endometriosis following ground-breaking preclinical results

Learn more about Gesynta Pharma

Gesynta Pharma

Gesynta Pharma bases its R&D on groundbreaking research from the Karolinska Institutet.

Our management

Our executive team and board of directors hold vast experience in drug development, commercialization and company scale-up.

Endometriosis

Endometriosis is a chronic, inflammatory, estrogen-dependent disease affecting millions of women worldwide.

Our portfolio

Our lead drug candidate vipoglanstat is in clinical phase II, while GS-073 is ready to enter clinical phase I.